# Cannabis caution as study finds increased psychosis risk for young people > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/cannabis-caution-as-study-finds-increased-psychosis-risk-for-young-people/ > **Published:** 2026-06-18T12:32:04-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T11:53:38-04:00 > **Clinical Summary:** Cannabis psychosis risk young adults requires psychiatric screening. Evidence, age cutoffs, and clinical decision-making for prescribers. --- ✦ New CED Clinical Relevance #47 Clinical Context Background information relevant to the evolving [cannabis medicine](https://cedclinic.com/essential-oils-industrial-hemp-antimicrobial-benefits/) landscape. Mental HealthResearchSafetyTHCPediatricsAnxietyNeurology Why This Matters Clinicians treating young patients must weigh cannabis’s potential benefits for anxiety and sleep against emerging evidence of increased psychosis risk, particularly given the developing adolescent brain’s vulnerability. This finding directly impacts clinical decision-making around cannabis recommendations and requires informed consent discussions that honestly address both [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) and serious psychiatric harms. Healthcare providers should implement age-stratified risk assessment protocols and consider alternative first-line treatments for mood and [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/) in younger populations pending further safety data. Clinical Summary A recent study examining [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) in young people identifies a significantly elevated risk of psychosis associated with regular consumption during adolescence and early adulthood, a critical period for brain development. While medicinal cannabis demonstrates efficacy for anxiety, sleep disorders, and depression in some populations, clinicians must carefully weigh these [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/) against the documented psychosis risk, particularly when treating younger patients who may be more neurobiologically vulnerable. The findings underscore the importance of age-stratified prescribing practices and suggest that alternative first-line treatments should be prioritized for adolescents and young adults presenting with mood or [anxiety disorders](https://cedclinic.com/adolescent-cannabis-use-and-anxiety-research/). Healthcare providers should engage in detailed risk-benefit discussions with younger patients and their families before initiating [cannabis therapy](https://cedclinic.com/cannabis-based-therapies-smoking-cessation/), with particular caution regarding high-potency products and frequent use patterns. Clinicians managing young patients should maintain heightened vigilance for early psychotic symptoms during and after cannabis exposure, including changes in perception, thought organization, or social functioning. For clinical practice, this evidence reinforces the principle that cannabis, while potentially therapeutic in select indications, should be reserved for adult populations with careful patient selection and requires informed consent discussions that explicitly address psychosis risk in youth. Dr. Caplan’s Take “We have peer-reviewed evidence showing increased psychosis risk in young people exposed to cannabis, particularly those with genetic vulnerability, and that’s something we cannot ignore in clinical practice. At the same time, we’re seeing separate literature suggesting benefit for anxiety and sleep in some populations, which means the conversation with each young patient needs to be individualized, risk-stratified, and honest about what we still don’t fully understand about long-term developmental effects.” Clinical Perspective 🧠 While cannabis is increasingly used by young people for self-management of anxiety, sleep, and mood symptoms, emerging evidence suggests that regular use during adolescence and early adulthood may elevate psychosis risk, particularly in genetically vulnerable individuals. This apparent paradox—that cannabis may provide symptom relief in the short term while potentially triggering or exacerbating serious psychiatric illness—complicates clinical decision-making and patient counseling. The causal mechanisms remain incompletely understood, and confounders such as underlying psychiatric vulnerability, frequency of use, cannabinoid composition, and route of administration make it difficult to quantify individual risk. Clinicians should screen for personal or family history of psychotic disorders before recommending or endorsing [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) for mood or anxiety symptoms in younger patients, and consider evidence-based alternatives as first-line treatments. When [cannabis use](https://cedclinic.com/cannabis-cardiovascular-health-insights-2024/) is already occurring, maintaining vigilance for early psychotic symptoms and having frank discussions about 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/forum/mental-health/) Have thoughts on this? Share it: [X Share on X](https://twitter.com/intent/tweet?text=Just%20read%20this%20on%20CEDclinic.com%3A%20Cannabis%20caution%20as%20study%20finds%20increased%20psychosis%20risk%20for%20young%20people%20%40drcaplan&url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59611)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59611)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just%20read%20this%3A%20Cannabis%20caution%20as%20study%20finds%20increased%20psychosis%20risk%20for%20young%20people%20via%20%40drcaplan.bsky.social%20https%3A%2F%2Fcedclinic.com%2F%3Fp%3D59611)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan)[📝 Read more on Substack](https://doctorapprovedcannabis.substack.com/)[🔔 Subscribe via RSS](https://cedclinic.com/feed/) Related Articles - [Cannabis, Tics, Tourette Syndrome, and OCD Symptoms](https://cedclinic.com/cannabinoids-for-tic-disorders-ocd/) - [`Adolescent Cannabis Use & Mental Health Risk: Clinical Evidence` – CED Clinic](https://cedclinic.com/adolescent-cannabis-use-mental-health-clinical-evidence/) - [High-Potency Cannabis Linked to Dramatically Higher Risk of Psychotic Episodes](https://cedclinic.com/high-potency-thc-cannabis-risk-psychotic-episodes/) 📰 Source: [https://medicalxpress.com/news/2026-06-cannabis-caution-psychosis-young-people.html](https://medicalxpress.com/news/2026-06-cannabis-caution-psychosis-young-people.html) Further Reading CED Clinic Blog[Why Cannabis Works](https://cedclinic.com/why-cannabis-works/) Evidence Watch[Cannabis and Heart Health](https://cedclinic.com/cannabis-cardiovascular-health-study/) CED Clinic Blog[Cannabis for Sleep](https://cedclinic.com/cannabis-for-sleep/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).